无多囊卵巢综合征女性胰岛素抵抗与体外受精结局的关联:二甲双胍治疗可能改善结局
这项观察性多中心回顾性队列研究纳入1033例无多囊卵巢综合征的不孕女性,比较胰岛素敏感组与胰岛素抵抗组及二甲双胍暴露与否的体外受精结局。胰岛素抵抗患病率为30.5%,未暴露胰岛素抵抗组较胰岛素敏感组临床流产风险更高、活产率更低;二甲双胍暴露的胰岛素抵抗患者临床妊娠率和活产率更高、临床流产风险更低。
要点
- 无多囊卵巢综合征不孕女性中胰岛素抵抗患病率为30.5%。
- 未暴露胰岛素抵抗组较胰岛素敏感组临床流产风险更高、活产率更低。
- 二甲双胍暴露的胰岛素抵抗患者临床妊娠率和活产率更高、临床流产风险更低。
核心结论
- 无多囊卵巢综合征不孕女性的胰岛素抵抗与较差的体外受精结局相关,胚胎移植前二甲双胍治疗与改善的生殖结局相关。
研究设计与样本
- 观察性、多中心、回顾性队列研究,临床数据来自西班牙私立生育中心,收集时间为2015年1月至2023年11月。
- 从1659例患者中,共1033例女性符合所有纳入标准且有可用数据进行分析。
- 纳入18至45岁、BMI≤30 kg/m2、有口服葡萄糖耐量试验结果、有使用供卵进行体外受精和胚胎移植指征的无多囊卵巢综合征不孕女性。
- 研究人群按口服葡萄糖耐量试验结果分为胰岛素敏感组(n=718)和胰岛素抵抗组(n=315)。
- 胰岛素抵抗患者中,198例首次胚胎移植时未暴露于二甲双胍,117例首次胚胎移植前暴露于二甲双胍。
主要发现
- 无多囊卵巢综合征不孕女性中胰岛素抵抗的患病率为30.5%。
- 与胰岛素敏感组相比,未暴露胰岛素抵抗组临床流产风险更高[26.3% vs 17.6%;校正相对风险(aRR)=1.439(1.078-1.921);P=0.013]。
- 与胰岛素敏感组相比,未暴露胰岛素抵抗组活产率更低[9.6% vs 24.5%;aRR=0.422(0.269-0.663);P<0.001]。
- 与未暴露胰岛素抵抗患者相比,暴露于二甲双胍的胰岛素抵抗患者临床妊娠风险更高[53.9% vs 35.9%;aRR=1.467(1.137-1.892);P=0.003]。
- 与未暴露胰岛素抵抗患者相比,暴露于二甲双胍的胰岛素抵抗患者临床流产风险更低[13.7% vs 26.3%;aRR=0.481(0.288-0.804);P=0.005]。
临床怎么用
- 作者认为,本研究结果为无多囊卵巢综合征不孕女性中胰岛素抵抗背景下子宫内膜环境对生殖结局的作用提供了有价值的信息。
- 作者指出,未来需要更大样本量的前瞻性研究来证实这些发现可推广至更广泛人群。
局限性
- 由于研究的回顾性性质,这项先导研究固有的局限性是研究组间可能存在异质性和混杂因素。
- 未来需要更大样本量的前瞻性研究来证实这些发现可推广至更广泛人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the association between insulin resistance (IR), metformin treatment, and the outcomes of IVF in IR infertile women without polycystic ovarian syndrome (non-PCOS)? SUMMARY ANSWER: IR among non-PCOS infertile women was associated with worse IVF outcomes compared to insulin-sensitive (IS) infertile women, and metformin treatment prior to embryo transfer (ET) was associated with improved reproductive outcomes. WHAT IS KNOWN ALREADY: Endometrium insulin-mediated glucose uptake is essential in human embryo implantation, decidualization, and pregnancy. IR has been described as a risk factor for spontaneous abortion in women undergoing IVF. While this condition has been studied in the context of PCOS and its association with poorer reproductive outcomes, with Metformin proposed as a possible treatment, there is a lack of studies examining the role of IR in non-PCOS infertile women. STUDY DESIGN, SIZE, DURATION: Observational, multicenter, retrospective cohort study with clinical data from private fertility centers in Spain collected between January 2015 to November 2023. From 1659 patients a total of 1033 women met all the inclusion criteria and had available data for analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included non-PCOS infertile women between 18 and 45 years old, with a BMI ≤30 kg/m2, available oral glucose tolerance test (OGTT) results, and an indication for IVF and ET using donated oocytes. The study population was stratified based on OGTT results in IS women (n = 718) and in IR women (n = 315). Among IR patients, we identified 198 who were not exposed to metformin at their first ET and 117 who were Metformin-exposed prior to their first ET. IVF outcomes, including biochemical pregnancy, biochemical miscarriage, clinical pregnancy, clinical miscarriage, and live birth rates were evaluated as primary outcomes in IS and not exposed IR groups. The association between metformin exposure and IVF outcomes among IR patients was assessed as secondary outcomes. MAIN RESULTS AND THE ROLE OF CHANCE: The prevalence of IR in non-PCOS infertile women was 30.5%. Compared to the IS group, unexposed IR women had a higher risk of clinical miscarriage [26.3% vs 17.6%; adjusted relative risk (aRR)=1.439 (1.078-1.921); P = 0.013] and lower live birth rates [9.6% vs 24.5%; aRR=0.422 (0.269-0.663); P < 0.001]. Alternatively, IR patients exposed to Metformin had a higher risk of clinical pregnancy [53.9% vs 35.9%; aRR = 1.467 (1.137-1.892) P = 0.003], lower risk of clinical miscarriage [13.7% vs 26.3%; aRR = 0.481 (0.288-0.804), P = 0.005], and higher live birth rates [40.2% vs 9.6%; aRR = 4.069 (2.445-6.774), P < 0.001] than unexposed IR patients. LIMITATIONS, REASONS FOR CAUTION: Due to its retrospective nature, the inherent limitations of this pilot study are the potential heterogeneity and confounding factors among the study groups. WIDER IMPLICATIONS OF THE FINDINGS: The findings of this study provide valuable insights into the role of the endometrial environment on reproductive outcomes in the context of IR among non-PCOS infertile women. Nevertheless, future prospective studies with larger sample sizes are essential to corroborate these findings to broader populations. STUDY FUNDING/COMPETING INTEREST(S): This project was supported by the Spanish Ministry of Universities through the Formacion de Profesorado Universitario Program (FPU21/01178) awarded to A.B.A, the Instituto de Salud Carlos III, cofounded by the European Social Fund (ESF) 'Investing in your future' through the Miguel Servet Program (CP20/00120) awarded to H.F. and (CP19/00149) awarded to I.C. and Sara Borrell Contract (CD23/00157) awarded to A.C. The authors have no conflicts of interest to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Albert AB, Corachán A, Juárez-Barber E, et al. Association of insulin resistance with in vitro fertilization outcomes in women without polycystic ovarian syndrome: potential improvement with metformin treatment. Hum Reprod. 2025. PMID: 40441707. doi:10.1093/humrep/deaf100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。